Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Down 1.3% – Should You Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares were down 1.3% on Tuesday . The stock traded as low as GBX 1 ($0.01) and last traded at GBX 1.10 ($0.01). Approximately 4,262,927 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 9,958,841 shares. The stock had previously closed at GBX 1.11 ($0.01).

Hemogenyx Pharmaceuticals Trading Down 1.4 %

The business has a fifty day moving average price of GBX 1.27 and a 200 day moving average price of GBX 1.34. The company has a market capitalization of £14.71 million, a PE ratio of -111.40 and a beta of 3.14. The company has a debt-to-equity ratio of 92.09, a quick ratio of 6.72 and a current ratio of 4.38.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.